{"id":20158,"date":"2024-03-31T10:37:50","date_gmt":"2024-03-31T14:37:50","guid":{"rendered":"https:\/\/arsacs.com\/?p=20158"},"modified":"2026-03-16T18:16:07","modified_gmt":"2026-03-16T22:16:07","slug":"omaveloxolone-testee-sur-la-souris-arsacs-drs-schmahmann-et-lin","status":"publish","type":"post","link":"https:\/\/arsacs.com\/fr\/omaveloxolone-testee-sur-la-souris-arsacs-drs-schmahmann-et-lin\/","title":{"rendered":"Omaveloxolone test\u00e9e sur la souris  ARSACS &#8211; Drs Schmahmann et Lin"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Cette <a href=\"https:\/\/arsacs.com\/fr\/physiological-and-behavioral-effects-of-omaveloxolone-in-an-arsacs-mouse-model-drs-schmahmann-and-lin\/\">recherche<\/a> est financ\u00e9e conjointement par la Fondation de l'Ataxie Charlevoix- Saguenay et le Massachusetts ARSACS Fundraiser, fonds cr\u00e9\u00e9 par des familles aux E.U. Des \u00e9tudes et essais cliniques r\u00e9cents ont d\u00e9montr\u00e9 que l\u2019omaveloxolone (nom de marque Skyclarys) peut am\u00e9liorer les sympt\u00f4mes cliniques de l\u2019ataxie de Friedreich. Drs. Schmahmann et Lin de l'Universit\u00e9 Harvard administreront Skyclarys \u00e0 un mod\u00e8le murin d'ARSACS et \u00e9tudieront si Skyclarys peut modifier l'\u00e9volution de la maladie chez ces souris. Nous pensons que les r\u00e9sultats de l'\u00e9tude propos\u00e9e seront essentiels pour d\u00e9terminer si l'omaveloxolone est appropri\u00e9e pour les essais cliniques dans l'ARSACS.<\/p>","protected":false},"excerpt":{"rendered":"<p>Cette recherche est financ\u00e9e conjointement par la Fondation de l&#8217;Ataxie Charlevoix- Saguenay et le Massachusetts ARSACS Fundraiser, fonds cr\u00e9\u00e9 par des familles aux E.U. Des \u00e9tudes et essais cliniques r\u00e9cents ont d\u00e9montr\u00e9 que l\u2019omaveloxolone (nom de marque Skyclarys) peut am\u00e9liorer les sympt\u00f4mes cliniques de l\u2019ataxie de Friedreich. Drs. Schmahmann et Lin de l&#8217;Universit\u00e9 Harvard administreront [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":20072,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-20158","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dernieres-nouvelles"],"_links":{"self":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/20158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/comments?post=20158"}],"version-history":[{"count":6,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/20158\/revisions"}],"predecessor-version":[{"id":24966,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/20158\/revisions\/24966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/media\/20072"}],"wp:attachment":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/media?parent=20158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/categories?post=20158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/tags?post=20158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}